Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical, is a clinical-stage biotech company engaged in biologic therapeutics as well as small molecule discovery and development.
If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.
